# US 2024/0392239 A1 · Methods for modulating cell pluripotency and self-renewal property

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0392239 A1
- Document ID: US20240392239A1
- Status: Published application
- Kind: A1
- Application number: 18/647,236
- Filed: 2024-04-26
- Published: 2024-11-28
- Earliest claimed: 2021-10-28
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan-Kettering Cancer Center
- Inventors: Lydia W.S. Finley; Paige K, Arnold; Benjamin T. Jackson
- Web page: https://patentgrep.com/patent/US20240392239A1

## CPC

- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Y 402/01003: Aconitate hydratase (4.2.1.3)
- G01N 33/5041: {involving analysis of members of signalling pathways}
- G01N 33/5073: {Stem cells}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N 2501/72: Transferases [EC 2.]
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to methods for modulating (e.g., maintaining) pluripotency and self-renewal property of cells (e.g., stem cells) by blocking the non-canonical tricarboxylic acid (TCA) cycle (e.g. using an inhibitor of ATP citrate lyase (ACL) or acetate), and kits and compositions relating thereto.

## Claims

### Claim at position 1

-48. (canceled)

### Claim 49

A method for maintaining pluripotency of cells, comprising blocking non-canonical tricarboxylic acid (TCA) cycle of the cells, wherein the blocking comprises contacting the cells with an ATP citrate lyase (ACL) inhibitor.

### Claim 50 (depends on 49)

The method of claim 49, wherein the ACL inhibitor is a synthetic ACL inhibitor, a natural ACL inhibitor, or a combination thereof.

### Claim 51 (depends on 49)

The method of claim 49, wherein the concentration of the ACL inhibitor is between about 10 μM and about 100 μM.

### Claim 52 (depends on 49)

The method of claim 49, wherein the cells are contacted with the ACL inhibitor for at least about 12 hours.

### Claim 53 (depends on 49)

The method of claim 49, wherein the cells are contacted with the ACL inhibitor for about 24 hours.

### Claim 54

A method for maintaining self-renewal property of cells, comprising blocking non-canonical tricarboxylic acid (TCA) cycle of the cells, wherein the blocking comprises contacting the cells with an ATP citrate lyase (ACL) inhibitor.

### Claim 55 (depends on 54)

The method of claim 54, wherein the ACL inhibitor is a synthetic ACL inhibitor, a natural ACL inhibitor, or a combination thereof.

### Claim 56 (depends on 54)

The method of claim 54, wherein the concentration of the ACL inhibitor is between about 10 μM and about 100 μM.

### Claim 57 (depends on 54)

The method of claim 54, wherein the cells are contacted with the ACL inhibitor for at least about 12 hours.

### Claim 58 (depends on 54)

The method of claim 54, wherein the cells are contacted with the ACL inhibitor for about 24 hours.

### Claim 59

A plurality of cells, wherein pluripotency of the cells is maintained, after blocking the non-canonical tricarboxylic acid (TCA) cycle of the cells, wherein blocking the non-canonical TCA cycle comprises contacting the cells with an ATP citrate lyase (ACL) inhibitor.

### Claim 60 (depends on 59)

The plurality of cells of claim 59, wherein the ACL inhibitor is a synthetic ACL inhibitor, a natural ACL inhibitor, or a combination thereof.

### Claim 61 (depends on 59)

The plurality of cells of claim 59, wherein the concentration of the ACL inhibitor is between about 10 μM and about 100 μM.

### Claim 62 (depends on 59)

The plurality of cells of claim 59, wherein the cells were contacted with the ACL inhibitor for at least about 12 hours.

### Claim 63 (depends on 59)

he plurality of cells of claim 59, wherein the cells were contacted with the ACL inhibitor for about 24 hours.

### Claim 64

A plurality of cells, wherein self-renewal property of the cells is maintained, after blocking the non-canonical tricarboxylic acid (TCA) cycle of the cells, wherein blocking the non-canonical TCA cycle comprises contacting the cells with an ATP citrate lyase (ACL) inhibitor.

### Claim 65 (depends on 64)

The plurality of cells of claim 64, wherein the ACL inhibitor is a synthetic ACL inhibitor, a natural ACL inhibitor, or a combination thereof.

### Claim 66 (depends on 64)

The plurality of cells of claim 64, wherein the concentration of the ACL inhibitor is between about 10 μM and about 100 μM.

### Claim 67 (depends on 64)

The plurality of cells of claim 64, wherein the cells were contacted with the ACL inhibitor for at least about 12 hours.

### Claim 68 (depends on 64)

The plurality of cells of claim 64, wherein the cells were contacted with the ACL inhibitor for about 24 hours.
